This week's roundup of Houston innovators includes Emmanuel Urquieta of TRISH, Ariel Jones of Qualtrics XM, and Lawson Gow of Pokatok. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space health research to sports tech — recently making headlines in Houston innovation.


Dr. Emmanuel Urquieta, chief medical officer of TRISH

Emmanuel Urquieta, chief medical officer of TRISH, joins the Houston Innovators Podcast. Photo via LinkedIn

Since 2021, the Translational Research Institute for Space Health has conducted its research on four missions — which has meant an unparalleled access to space health data for TRISH.

“We really saw the value of implementing research in civilians because they are different from your traditional government astronaut,” Dr. Emmanuel Urquieta, chief medical officer for TRISH, says on the Houston Innovators Podcast. “In civilians, you see a more diverse population.”

Urquieta says TRISH's experiments on these missions all fall within a few pillars of space health, including space's effects on sensory motor skills, like balance and motion sickness, as well as mental health, environmental data from the vehicles, vital monitoring, and more. Read more.

Ariel Jones, head of health care provider solution strategy for Qualtrics XM

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe. Photo courtesy

In a guest column for InnovationMap, Ariel Jones, head of health care provider solution strategy for Qualtrics XM, addresses inequalities in health care — and how technology, specifical experience management tech, can help bridge the gap.

"As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe," she writes. Read more.

Lawson Gow, co-founder of Pokatok

A new sports festival is headed to Houston next year. Photo courtesy of Pokatok

Pokatok, the recently announced, four-day sports festival is slated to take place April 4-7, 2024.

“Pokatok will not only be the largest gathering of the entire sports tech ecosystem, it will also be a true fan festival for sports enthusiasts,” says Gow in the news release. “Everyone speaks the language of sport, it’s an incredibly powerful unifier of our society, and this festival will bring together people from around the world to experience hundreds of events revolving around the new and the next in sport.”

The festival, which has secured support from Houston First, the Greater Houston Partnership, and the Harris County Houston Sports Authority to put on the event, will feature two tracks — one focused on sports innovation and the other surrounding a fan experience. Pokatok X will include an expo and showcase focused on sports innovation, bringing together startups, investors, accelerators, athletes, and industry experts to dive into sports tech. Read more.

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe. Photo via Getty Images

Houston expert: How technology can be used to bridge the health equity gap

guest column

Progressively over the last decade, the health care industry has become increasingly aware of the role that social determinants of health play in the health outcomes of patients.

Social determinants of health, or SDOH, are the conditions in which people are born, grow, live, work, and age, and they have a significant impact on a person's health and well-being. Examples of SDOH include income, education level, housing, and access to healthy food.

One of the key challenges facing health care organizations and providers is how to address health equity gaps, which are the differences in health outcomes between different populations. Health equity gaps are often caused by social determinants of health, and they can be particularly pronounced among vulnerable populations such as low-income communities, racial and ethnic minorities, and those living in rural areas.

Experience management technology has emerged as a powerful tool for addressing these equity gaps. This technology uses feedback, behaviors, and other relevant SDOH data in order to understand the unique needs of different populations and develop targeted interventions to improve their health outcomes.

One of the key ways that experience management technology can help decrease health equity gaps is by segmenting populations by social determinants of health. By collecting data on patients' demographics, such as their age, race, income, and education level, health care organizations can gain a better understanding of the SDOH that are most relevant to each population. This information can be used to develop personalized actions that address the specific needs of each population, rather than relying on a one-size-fits-all approach.

For example, health care organizations could use experience management technology to gather feedback from patients on their access to healthy food. By segmenting the patient population by zip code, health care organizations could identify patients in rural areas who do not have easy access to quality care facilities and providers. These patients could then be targeted with interventions such as transportation assistance programs or care coordination programs, which could help address their specific needs.

In addition to segmenting populations by social determinants of health, experience management technology can also help health care organizations gather insights into patient behaviors. By integrating data on patients' health behaviors, such as adherence to treatment or missed appointments, health care organizations can develop targeted interventions that encourage healthy behaviors.

For example, health care providers could use experience management technology to collect data on patients' treatment habits. Patients who report low adherence to treatment could be targeted with interventions such as treatment education programs or care coaching, which could help them develop healthier habits over time.

Finally, experience management technology can help health care organizations gain insight into their patient’s end to end journey. By integrating data from multiple sources, such as electronic health records, patient feedback, and social determinants of health data, health care organizations can develop a more comprehensive understanding of patients' health needs and brand expectations. This unified illustration allows health care organizations to improve business outcomes such as lower readmission rates, and create loyal patients that will refer their friends and family in the most important and sensitive moments in their lives.

In conclusion, experience management technology has emerged as a powerful tool for addressing health equity gaps by segmenting populations by social determinants of health, understanding and acting on their unique needs through feedback, behaviors, and dynamic integrations. By leveraging this technology, health care organizations can develop unique solutions that improve the health outcomes of vulnerable populations, such as low-income communities, racial and ethnic minorities, and those living in rural areas.

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe.

------

Ariel Jones is the head of health care provider solution strategy for Qualtrics XM, an American Experience Management company providing software solutions for customer and employee experience.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”